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Novelty Statement 
 HbA1c determination from dried blood spots has been reported but results have been 
affected by stability issues, requiring methodologies which have included extended 
drying periods, and storage at low temperatures or for a limited period of time  
 HbA1c levels determined from HemaSpot™ blood collection devices show a strong 
correlation with venous HbA1c results, with the potential for calibration against the 
venous method used. 
 Patient acceptance of the blood collection method was high, with 61.7% of 
participants indicating that they would be more likely to have their testing carried out 
if this method of blood collection was available. 
 By providing patients with an opportunity to increase compliance with regular HbA1c 
testing, use of venous calibrated HbA1c determination from HemaSpot™ blood 
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HbA1c monitoring in the Scottish Highlands is by HPLC analysis of GP collected venous 
samples at a centralised laboratory. Availability of HbA1c results at clinic appointments is less 
than ideal due to patient reticence and availability/timeliness of appointments.  This study 
assessed the clinical performance and patient acceptance of HemaSpot™ blood collection 
devices as an alternative blood collection method.  
Methods 
Adult men and women with any type of diabetes, routinely carrying out self-monitoring of 
blood glucose were recruited (n=128). Participants provided a venous blood sample and 
prepared two HemaSpot™ dried blood spots (DBS), one at clinics and one at home.  HbA1c 
analysis was by TOSOH G8 HPLC. Participants also completed a questionnaire. 
Results 
A strong linear relationships between HbA1c levels in dried blood spots and venous blood 
were observed and a linear model was fitted to the data.  Time between dried blood spot 
preparation and testing did not impact the model. 
Participants were accepting of the approach, 69.2% would use this system if available and 
60.7% would be more likely to use this system than going to their GP.  
 
Conclusions 
The combination of a robust desiccating dried blood spot device, home sample preparation 
and return by post produces HbA1c data which supports use of a time-independent linear 
calibration of dried blood spot to venous blood HbA1c. A robust remote sample collection 
service would be valuable to people living with diabetes in urban areas who are working or 
house-bound as well as those living in remote or rural locations. 
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Introduction   
The benefits of good blood glucose control in preventing long term complications of diabetes 
are well documented [1].  Complications, arising from poor blood glucose control over 
extended periods, place an economic burden on health services and significantly reduce 
health-related quality of life in people with diabetes [2,3]. 
 
Ongoing blood glucose control is assessed by regular measurement of HbA1c, with several 
laboratory methods available for use with fresh blood obtained using either venepuncture or 
by fingerprick with collection in capillary tubes.  Point-of-care instruments are now available 
for measuring HbA1c levels in fresh capillary blood [4]. 
 
In the Scottish Highlands (NHS Highland Health Board area) HbA1c determinations are 
performed centrally in Inverness using ion-exchange HPLC analysis (TOSOH G8 HPLC 
analyser (TOSOH Bioscience, Tokyo, Japan)) on venous blood samples collected locally at 
GP practices. If there is no recent HbA1c result, DCA Vantage point-of-care instruments  
(Siemens Healthcare) are used at hospital appointments. 
 
Current sampling methods are acceptable in terms of HbA1c determination, however the use 
of venepuncture with centralised testing is not providing users in the NHS Highland area with 
an acceptable approach as evidenced by the frequency with which HbA1c results are not 
available at clinical appointments.    
 
Individualised HbA1c targets should be agreed and regularly reviewed at diabetes 
appointments with clinicians, and lifestyle and/or medication changes discussed with the aim 
of optimising HbA1c levels.  The value of diabetes appointments where HbA1c levels are not 
available is greatly diminished.  For hospital based appointments, point-of-care instruments 
are available for immediate HbA1c determinations. However the vast majority of people with 
diabetes (those with uncomplicated type-2 diabetes) are managed in the community by GPs 
where point-of-care instruments are not generally available.  In our local Health Board area 
the cost of HbA1c analysis is borne by secondary rather than primary care so the costs and 
maintenance implications of GP based point-of-care instruments are not straightforward. 
 
Method and convenience of place of collection and timeliness of results are potential factors 
which impact the availability of HbA1c results at appointments and consequently impact the 
opportunity for discussion of HbA1c levels and targets.  
 
In line with recognition by the UK and Scottish government that “patients need to be 
empowered to manage their care” [5.6], the long term aim of our approach is for people with 
diabetes to be able to take responsibility for sending off their own blood samples and for 
results to be sent directly to them so that they can attend review appointments having had the 
opportunity to reflect on their latest HbA1c result and what it might mean for them in terms of 
their individual HbA1c target.  To address this aim we have identified a robust blood sampling 
device (HemaSpot™, Spot on Sciences Austin, Texas, US) for preparing dried blood spots 
(DBS) which has the potential to fulfil the requirements of our overall approach. 
 
HemaSpot™ blood collection devices comprise a robust plastic wallet enclosing an eight 
bladed filter paper surrounded by desiccant (Fig. 1). A protective cover allows blood 
application through a central hole.  The device is designed to absorb two hanging drops of 
blood, equivalent to about 65-105µl blood. 
 
The use of filter papers for collection of dried blood spots is accepted as an alternative method 
of blood collection for a variety of applications [7] as they are simple to prepare, have low 
costs of collection and transport, and are safer and more acceptable to study participants [8). 
 
A systematic review identified 17 studies using dried blood spots for HbA1c [9] with two extra 
studies recently published [10, 11].  Variation and bias increase with increasing time between 
sample preparation and testing have been observed, meaning that even when HbA1c can be 
calibrated against standard venous HbA1c, calibration needs to consider the time between 
sample preparation and testing.    
 
A laboratory based study previously carried out in our laboratory compared HbA1c analysis of 
laboratory prepared HemaSpot™ dried blood spots (n=40) with HbA1c values obtained from 
fresh capillary blood.  A strong correlation between HbA1c from dried blood spots and fresh 
capillary blood was observed, suggesting that HemaSpot™ devices have the potential to be 
used as an alternative to current blood collection methods if they were well calibrated using a 
linear model and dried blood spots were tested within three days of preparation (see 
Supplementary Material Table 1).   
 
The purpose of the current study was to assess the clinical performance and user acceptability 
of dried blood spots prepared using HemaSpot™ devices by people with diabetes at home, as 
an alternative blood sample collection method for HbA1c determination.  
 
Participants and Methods 
 
Recruitment 
Participants (128) were recruited when they attended their routine diabetes clinic 
appointments in Inverness. It was anticipated that this number of participants would provide 
at least the recommended 100 returned home dried blood spot samples for comparison [12]. 
 
Adult men and women, aged 18-75 years, with any form of diabetes and regularly carrying 
out self-monitoring of blood glucose (SMBG) were included in the study.  Pregnant women 
and patients receiving renal replacement therapy were excluded. 
 
All participants gave written informed consent.  NHS research ethics approval was obtained 
(16/NW/0214).  
 
While attending diabetes clinics, venous blood samples were taken for routine HbA1c analysis.  
Under the guidance of a research nurse participants prepared dried blood spots from finger 
prick blood using HemaSpot™ blood collection devices by applying blood from a hanging 
drop of blood until the filter paper in the device was visibly filled. HemaSpot™ devices were 
closed immediately after blood application and stored at 4°C until analysis. 
 
Participants were given a home pack which included a dried blood spot preparation kit, 
questionnaire and information about HbA1c. Free post envelopes were provided for return of 
home prepared dried blood spots and questionnaires.  Participants were asked to post their 
dried blood spot on the day of preparation. 
 
Questionnaire 
A 5-point Likert scale 17 question questionnaire assessed participant experience of preparing 
dried blood spots, thoughts on a remote HbA1c service and views on the information provided 
about HbA1c.   
 
HbA1c analysis 
HbA1c analyses were performed using the Tosoh HLC 723-G8 (HPLC analyser (Tosoh 
Bioscience, Tokyo, Japan) using a cation exchange TSKgel variant HSi column. The column 
was calibrated to International Federation of Clinical Chemistry  using Tosoh calibrators. 
Lyphocheck Diabetes bi-level controls (Bio-Rad Laboratories, California, USA) were used 
daily, with CVs  of 2% for the low control  (mean of 33mmol/mol (5.2%)), and  0.9% for the 
high control  (mean of 78 mmol/mol (9.3%)).   
 
Blood from dried blood spot samples was eluted by placing 1 HemaSpot™ filter blade in 1ml 
Hemolysis/Wash solution for 2 hours at ambient temperature.  For analysis, 4µl of eluate were 
aspirated by the analyser before injection onto the column. 
 
Dried blood spots were stored at 4°C in the laboratory. Processing and analysis was 
performed within four days of preparation. 
 
Chromatograms were assessed visually using the G8 Operator’s Manual specifications for 
results acceptability, with guidance from the software flags.   
 
Data analysis  
Data analysis was carried out using IBM SPSS versions 19/20 for Windows (IBM 
Corporation, NY, USA), R and Excel software (Microsoft Corporation, WA, USA).  
Correlation between sample collection methods was investigated using Pearson coefficient 
and regression analysis. Agreement and bias between sample collection methods was 
investigated using Bland-Altman plots. Statistical significance was determined at the 5% 
level. 
Covariates that were considered to be potential confounders were tested separately to one 
another within the general linear model  and as a full interaction with the main predictor 
variable (home result) to assess whether the confounder was affecting the relationship (i.e. the 
calibration) between the home result and the venous reading. Nested models (with and 
without the additional covariate) were tested for statistical significance using an F-test (using 
the function “anova()” in R) 
 
Results   
  
Participant Characteristics 
Participant characteristics are presented by type and duration of diabetes (Table 1). More 
women (61.3%)  than men with type 1 diabetes and more men (69.0%) than women with type 
2 diabetes participated, however the overall numbers of men (N=53)  and women (N=51) 
participants were similar.   
 
Blood samples available 
HbA1c results were available for 127 venous blood samples, 125 clinic and 104 home 
prepared dried blood spots.  Minimum and maximum times between home dried blood spot 
preparation and testing were 1 and 4 days, with 38.5%, 43.3%, 16.3% and 1.9% of samples 
tested on days 1, 2, 3 and 4 respectively.  
 
HbA1c analysis 
HbA1c from both home and clinic prepared dried blood spot types exhibit strong correlations 
with venous HbA1c (R2 values close to 0.98), (Fig. 2). There is a significant difference 
between the clinic and home dried blood spot relationships with venous blood. We have 
excluded the time between sample preparation and HbA1c analysis as a potential source of the 
difference. Early transfer of clinic prepared dried blood spots to storage at 4°C differs from 
home dried blood spot treatment immediately after preparation, however we have not been 
able to confirm or exclude this as a reason for the difference observed. 
 
The mean bias of home dried blood spots, compared with venous blood, across the 
measurement range was +4.27mmol/mol (+0.39 %).  A plot of the absolute differences 
against the mean of venous and home dried blood spot HbA1c indicates that the absolute 
difference increases with the mean of the pair (Fig. 3), suggesting that whilst home dried 
blood spot HbA1c results may not be used directly as an equivalent to venous results they may 
be successfully calibrated against one another.  A general linear model was used to establish a 
calibrating relationship between home dried blood spot results and venous results.  Diagnostic 
plots supported the assumption of normality amongst residuals and did not suggest 
heterogeneity of variance, supporting the use of this model.  
 
The model fitted is: 
[HbA1c]Venous = 1.18[HbA1c]HomeDBS -7.5 (mmol/mol) 
[HbA1c]Venous= 1.18[HbA1c]HomeDBS - 0.69 (%) 
 
The model allows prediction of venous blood HbA1c levels from dried blood spot HbA1c 
results.  Concordance values were 100%, 92.5% and 96.6% between venous and predicted 
values from home dried blood spots for HbA1c values of <48 mmol/mol (<6.5%), 48-64 
mmol/mol (6.5-8%) and >64 mmol/mol (>8%) respectively.  
  
The model holds only for the range of HbA1c values in the study sample (35-115 mmol/mole 
(5.4 – 12.7%)) and when HbA1c analysis from HemaSpot™ is performed using a TOSOH G8 
Analyser.   
 
A number of covariates were individually tested to assess how they affected the calibration, 
using a set of nested linear models with each of the variables added separately to the main 
model (Table 2).   Of the covariates tests, only a laboratory factor covariate (with lab staff 
carrying out the test as a proxy) statistically significantly affected the results.  
   
Questionnaire 
One hundred and ten (86%) questionnaires were returned.  Of these, 101 had a corresponding 
home dried blood spot sample.    
 
The majority (99.1%) of respondents found the instructions easy to use and 83.5% found it 
easy to get their HemaSpot™ in the post on time. Obtaining enough blood, blood application 
to the device and deciding when there was enough blood on the device was less easy (Table 
3).  
When asked if they would use the system if it was available, 69.2% of respondents agreed, 
while 61.7% agreed that they would be more likely to use a dried blood spot system than 
making an appointment with their practice nurse.  A similar percentage (60.7%) agreed they 
would have a preference for using this system at home compared with having blood taken at 
their GP surgery.   
 
Sixty per cent of respondents agreed that they would be more likely to have their HbA1c test 
done if the system was available, while 50.0% of respondents felt that using a system like this 
would help them to feel more in control of their diabetes. 
 
The majority (88.0%) of respondents found the information provided about HbA1c interesting 
and 81.5% found the information useful. 
 
Discussion  
The principal finding from the study is that HemaSpot™ dried blood spots prepared by study 
participants at home and analysed using the TOSOH G8 system, produce clinically acceptable 
HbA1c results when the dried blood spot method is calibrated to TOSOH G8 determined 
venous HbA1c results using a general linear model.  Time between sample preparation and 
testing did not significantly affect the calibration up to 4 days.  For this analysis the 
unbalanced nature of the number of observations in each “bin” (i.e. number of days between 
sampling time and testing) is not preferred but doesn’t violate any of the assumptions in a 
general linear model such as this. It merely reduces the statistical power of the test. 
 
A statistically significant effect on calibration was observed for the laboratory factor covariate 
tested (Table 2), where laboratory personnel has been used as a proxy. For example, as a 
consequence of logistics, there may have been a relationship between the personnel and the 
day, or time of day, on which a sample was tested. It is also possible that a type I error has 
occurred (given that 5 statistical hypotheses were tested, there is an estimated 23% chance of 
a type I error). In favour of the hypothesis that a type I error may have occurred is that for 
each of the particular proxies the additive and interaction terms affecting the calibration 
relationship all had confidence intervals encompassing zero– i.e. no individual proxy appears 
to be statistically or clinically significantly from the rest.  For full details see Supplementary 
Material Table 2. 
 
Several HbA1c dried blood spot studies have been published [10,11,13,14,15] with analysis by 
turbidimetric inhibition immunoassay [13,16,17,18], HPLC analysis [10,11,15,19,20] and 
affinity chromatography [21,22].  A systematic review and meta-analysis by Affan et al 
reported that, although results from venous and dried blood spots were different, there was 
close agreement (meta-analysis regression equation: [HbA1c]DBS = 0.9553[HbA1c]venous + 
0.2566 (%)) between venous and dried blood spot samples, except when analysis was by 
affinity chromatography [9]. Slope and intercept ranges in the meta-analysis were 0.88-1.25 
and 0.002-1.8 (units: %) respectively.  Our model slope and intercept fit within these ranges, 
however the model is only valid when used with the measurement method used in our study. 
 
In vitro glycation of haemoglobin and degradation of HbA1c during storage have been 
suggested as possible reasons for differences observed between dried blood spots and fresh 
blood sample [13, 23].  Our results show increasing bias as HbA1c increases which supports 
the in vitro glycation theory due to increased blood glucose levels (and hence in vitro 
glycation) associated with higher HbA1c levels.    
 
Precision of dried blood spot sample elution and analysis method was assessed by repeat 
analysis of high and low QC samples which had been applied to filter papers and eluted using 
the dried blood spot sample elution and analysis protocol described. CVs were comparable to 
CVs reported for fresh blood analysis suggesting that minimal error is introduced due to dried 
blood spot sample elution and analysis protocols.. 
 
Both venous blood collected in EDTA tubes [11,14,16,18,19,24] and finger prick capillary 
blood [10,13,15,17,20,21,22] have been used to prepare dried blood spots on filter paper with 
drying times ranging from 20 minutes [22] to overnight [22] reported, before placing the dried 
blood spots in a storage bag or envelope.  The HemaSpot™ device has no requirement for a 
pre-drying step. 
 
With the exception of two previous studies [10, 13], dried blood spots have been prepared by 
health care professionals or researchers.  For routine, remote monitoring of HbA1c, a dried 
blood spot approach needs to be evaluated in the hands of the end user.  Our findings show 
acceptable clinical results when dried blood spots were prepared by users.  
 
Stability of HbA1c on dried blood spots has been a concern with an indication that a time 
dependent calibration for estimating venous HbA1c levels from dried blood spots is required 
[15,16].  Our findings suggest that with the HemaSpot™ device a single calibration could be 
used for samples tested up to 4 days after preparation. 
 
In agreement with our findings, high patient satisfaction with a potential dried blood spot 
HbA1c monitoring system has previously been reported in The Netherlands [13]. 
 
Although participants in our study reported that instructions were easy to follow, several 
participants found difficulty with blood application and in deciding when there was sufficient 
blood on the device. Comments included “I don't think I got enough blood into the device”, 
and “does take a bit of work to "fill" the device to the edges”.  However concern about 
sufficient filling was not reflected in the results, where a strong correlation between venous 
and dried blood spot HbA1c results was observed. The difficulties reported could be overcome 
by inclusion of photographs of sufficiently and insufficiently filled devices in the instructions, 
to give patients confidence that they are providing an adequate amount of blood for analysis.  
Additional tips on blood application could also be incorporated.  
 
A number of participants felt that they would still prefer to have an appointment at their GP 
practice both because they had other tests carried out at the same time and valued time spent 
with their health care professional.  One participant wrote “When visiting the nurse for a 
HbA1c I also get my blood pressure, weight, and feet checked and the opportunity for 
questions and instructions/guidance from the nurse. I would miss this testing at home”. The 
introduction of a remote monitoring service for HbA1c needs to consider not only what might 
be gained by this approach, but also what patients might lose through lack of contact with 
health care professionals.   
 
Provision of information about HbA1c was welcomed by participants.  The opportunity to 
provide simple clear information about HbA1c and its importance in management of diabetes 
should be considered in any remote HbA1c monitoring approach. 
 
The combination of a robust desiccating dried blood spot device, home sample preparation 
and return by post, to our knowledge, has not been reported for HbA1c, and provides the 
opportunity to introduce a remote sample collection service which would be equally valuable 
to people living with diabetes in urban areas who are working or house-bound as well as those 
living in remote or rural locations. 
 
The observation that the time between sampling and testing did not  significantly affected the 
linear model indicates that use of the HemaSpot™ device might enable a single model to be 
used that is independent of the time between preparation of the dried blood spot and the day 
of testing.  
 
Further studies are planned to assess the performance, acceptability and service delivery 
options of HemaSpot™ dried blood spots prepared by people with diabetes managed in the 
community.   
 
The health economics of introducing a remote HbA1c monitoring service using HemaSpot™ 
devices needs to be assessed, taking into consideration both the immediate impacts on costs 
and the longer term costs associated with complications.  
 
Study Limitations 
Some limitations of the study should be noted.  First, participants were all regularly carrying 
out SMBG and so were familiar with obtaining drops of capillary blood.  The wider diabetes 
community will have the same familiarity so this is a population in which the model derived 
in the study would need to be validated prior to practical application.   Second, only one batch 
of HemaSpot™ devices was available to evaluate over the period of study so it was not 
possible to assess the impact of batch to batch variation.  Third, the study focused only on 
analysis of HbA1c using the TOSOH HbA1c analyser, the method used in the laboratory where 
routine HbA1c analyses for the region are performed.  Fourth, the difference observed between 
clinic prepared and home prepared dried blood spots remains unexplained and warrants 




HbA1c monitoring plays a pivotal role in preventing complications of diabetes and therefore in 
achieving as good a quality of life as possible.  The HemaSpot™ blood collection device 
provides an opportunity for improvements in rates of HbA1c monitoring and more effective 
consultations. Increased participation by the diabetes community in self-management would 
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Duration of diabetes 
(years) 
   Mean Minimum Maximum Mean Minimum Maximum 
Type 1 Women 38 48.8 19 71 26.8 3 60 
 Men 24 44.8 19 71 19.3 0.1 44 
 Total 62 47.3 19 71 23.9 0.1 60 
         
Type 2 Women 13 55.6 31 69 12.0 2 20 
 Men 29 64.0 39 84 14.0 0.3 44 
 Total 42 61.4 31 84 13.4 0.3 44 
         
Total 
population 
 104 53.0 19 84 19.6 0.1 60 
 
 
Table 2. The effect of the addition of potential covariates on top of the base model of the 
venous reading (dependent variable) regressed against the home result (the independent 
variable). Each additional covariate was added separately and as a full interaction with the 
home result. Each nested pair of models (without covariate and with) were compared using an 
analysis of variance. For each nested pairwise comparison of models the data set used was the 
full data set, less any observations that had missing data for either the home result or the 
added covariate.  For further details see Supplementary Material Table 2.    
 
Additional covariate p-value for full interaction cf base 
model 
Own Lancet (Y=27, N=74) 0.40 
Type of Diabetes (Type 1=64, Type 2=42) 0.47
Sex (F=52, M=53) 0.11
Time between sampling & testing (N=105) 
(Days(n): 1(39),   2(47),  3(17) and  4(2)) 
0.30 







Table 3. Analysis of questionnaire responses to questions relating to experience of using and 
potential use of the HemaSpot™, and the information provided about HbA1c. The total 
number of responses to each question (n) is shown in the left hand column. 
 
I found….. 
Easy or very 





Difficult or very 
difficult (%) 
..following the instructions (n=108) 99.1 0 0.9 
..using the lancet provided (n=94) 89.4 8.5 2.1 
..getting my sample in the post on time (n=109) 83.5 7.3 9.2 
..getting enough blood (n=109) 50.5 21.1 28.4 
..applying the blood to the device (n=108) 44.5 22.2 33.3 
..deciding when I had applied enough blood (n=109) 56.9 20.2 22.9 









Would use if available (n=107) 69.2 11.2 19.6 
More likely to use than making an appointment with 
practice nurse (n=107) 
61.7 15.0 23.3 
Prefer to use this system at home compared with 
having blood taken at  GP (n=107) 
60.7 17.8 21.5 
More likely to have HbA1c test done (n=107) 59.8 15.0 25.2 
Help feel more in control of my diabetes (n=106) 50.0 22.6 27.4 
Prefer to have pack sent to them by post (n=105) 66.7 15.2 18.1 
Happy to collect pack from GP (n=104) 51.0 19.2 29.8 
Found information sheet about HbA1c interesting 
(n=108) 
88.0 10.2 1.9 
Found information sheet about HbA1c useful (n=108) 81.5 16.7 1.8 
HbA1c information sheet detail about right (n=109) 83.5 14.7 1.8 
Would like HbA1c information sheet to be more 
detailed (n=107) 
28.0 32.7 39.3 
 
 
Legends for figures 
 
Figure 1 The HemaSpot™ blood collection device showing the blades of the fan shaped filter 
paper (in red).  Once blood has been applied through the hole in the application surface the 
device is folded over and snapped shut.  Image courtesy of Spot on Sciences. 
 
Figure 2. Home and clinic prepared DBS HbA1c plotted against venous HbA1c. Home DBS: 
solid symbols, dotted line. Clinic DBS: open symbols, dashed line.   
  
Figure 3. Bland-Altman plot, the difference between venous and home DBS HbA1c showing 
evidence of a straight line relationship between the absolute difference and the mean values 






(solid line, solid symbols)
y = 0.8306x + 7.52 (mmol/mol)
(y=0.8306x + 1.05 (%))
R² = 0.9794
Clinic DBS 
(dashed line, open symbols)
y = 0.9098x + 2.79 (mmol/mol)
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Mean of home and venous DBS HbA 1c, mmol/mol (%)
20                      40                        60                       80                      100                     120                          
(4.0)                   (5.8)                     (7.6)                   (9.5)                  (11.3)                 (13.1)
16
(1.55)
10
(0.91)
4
(0.37)
-2
(-0.18)
